NEW YORK (TheStreet) -- Hologic (HOLX) ended its fiscal year on a disappointing note as 2014 guidance failed to impress.
The women's health care specialist pegged revenue for fiscal 2014 between $2.425 billion to $2.475 billion and earnings in the range of $1.32 to $1.38 a share. Analysts surveyed by Thomson Reuters forecast profit of $1.62 a share on revenue of $2.585 billion.
Pushing projected revenue lower was weak demand for ThinPrep pap tests, the mammography system 2D Selenia and its heavy menstruation surgical solution NovaSure, the company said.
"We expect fiscal 2014 to be a transitional year for the company," said CEO Jack Cumming in a statement. During a conference call, Chief Financial Officer Glenn Muir added that guidance represented a "realistic view of this coming year" and that top- and bottom-line growth in the low to mid-single digits would return in 2015.
Investment firm Canaccord downgraded the stock to a "hold" rating and lowered its price target to $19 on the weaker-than-expected guidance.
"While we recognize management is likely attempting to mitigate quarterly misses and suggested FY15 should stabilize, we think growth will remain challenged," the report said.
Jefferies was a touch more optimistic, maintaining its "buy" rating but lowering its price target to $24 from $26.
"While a cut to guidance was expected, and even welcome given the recent string of disappointing results, the complexion of what Hologic offered was far from comforting," the report said. "While this outlook could simply be conservatism, the company still has a lot of work to do to do to win back investor confidence."